Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Stryker Corporation (SYK), Johnson & Johnson (JNJ): This Niche Player Will Make Investors Rich

Page 1 of 2

A lot of investors feel safe buying enormous conglomerates that dominate an industry, but few take notice of smaller players that dominate a niche. That’s part of the reason why Stryker Corporation (NYSE:SYK) is on sale today at a price that could make investors rich.

Stryker Corporation (NYSE:SYK)

Thriving in its Niche

Stryker is very good at inventing and producing orthopedic equipment. It basically expands the niche on its own by creating innovative new products.

The company has a moat in the form of expertise in developing orthopedic equipment; very few firms can match the expertise that Stryker Corporation (NYSE:SYK) has.

A significant portion of Stryker’s revenue comes from high-quality knees and hips. Unfortunately, Stryker is not the only company in this niche. Zimmer Holdings, Inc (NYSE:ZMH) is also a global supplier of knees and hips — though it is only about half the size of Stryker as measured by sales.

In addition, Zimmer is heavily exposed to Europe. The company’s European business has been hit hard by the Euro-zone crisis, which shows no signs of alleviating. As long as Zimmer is still bogged down financially by the poor economic environment in Europe,  Stryker Corporation (NYSE:SYK) should continue to improve relative to its primary competitor.

Bright Future

Stryker has a bright future ahead of it. Its medical equipment segment represents an enormous growth opportunity despite being only a small part of the company today. The company is also continuing to innovate in areas outside of orthopedic equipment, such as its upcoming stroke care toolkit.

Demographics are clearly in Stryker’s favor as the world population ages. But more exciting in my view is the fact that the company has $2.2 billion in cash on its balance sheet. Management has proven to be adept at making value-creating acquisitions to enter new markets — as it did with its January 2013 acquisition of Trauson Holdings to enter the Chinese market. Prudent acquisitions continue to be a major growth driver at the firm.

Competition From Conglomerates

Stryker Corporation (NYSE:SYK) faces some competition from conglomerates like Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is one of the most recognizable brands in the world, with a diversified set of high quality healthcare businesses that make the company a market leader in most of the spaces in which it competes. It also generates lots of free cash flow from one of the best drug pipelines in the industry.

Page 1 of 2
Loading Comments...